{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:29:33Z","timestamp":1769639373873,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00204-024-03895-z","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T17:46:24Z","timestamp":1731606384000},"page":"377-391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanisms"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8687-9885","authenticated-orcid":false,"given":"Vlasia","family":"Kastrinou-Lampou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Rodr\u00edguez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birk","family":"Poller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Huth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko S.","family":"Schadt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd A.","family":"Kullak-Ublick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Arand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian","family":"Camenisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"issue":"1","key":"3895_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1021\/acs.chemrestox.9b00262","volume":"33","author":"MD Aleo","year":"2020","unstructured":"Aleo MD, Shah F, Allen S, Barton HA, Costales C, Lazzaro S, Will Y (2020) Moving beyond binary predictions of human drug-induced liver injury (DILI) toward contrasting relative risk potential. Chem Res Toxicol 33(1):223\u2013238. https:\/\/doi.org\/10.1021\/acs.chemrestox.9b00262","journal-title":"Chem Res Toxicol"},{"issue":"8","key":"3895_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2021.158960","volume":"1866","author":"MD Appelman","year":"2021","unstructured":"Appelman MD, Wettengel JM, Protzer U, Oude Elferink RPJ, van de Graaf SFJ (2021) Molecular regulation of the hepatic bile acid uptake transporter and HBV entry receptor NTCP. Biochim Biophys Acta Mol Cell Biol Lipids 1866(8):158960. https:\/\/doi.org\/10.1016\/j.bbalip.2021.158960","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"6","key":"3895_CR3","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/hep.20961","volume":"42","author":"N Ballatori","year":"2005","unstructured":"Ballatori N, Christian WV, Lee JY, Dawson PA, Soroka CJ, Boyer JL, Li N (2005) OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. Hepatology 42(6):1270\u20131279. https:\/\/doi.org\/10.1002\/hep.20961","journal-title":"Hepatology"},{"issue":"2","key":"3895_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/hep.20800","volume":"42","author":"E Bjornsson","year":"2005","unstructured":"Bjornsson E, Olsson R (2005) Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42(2):481\u2013489. https:\/\/doi.org\/10.1002\/hep.20800","journal-title":"Hepatology"},{"issue":"2","key":"3895_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.11648\/j.ijpc.20190502.11","volume":"5","author":"G Camenisch","year":"2019","unstructured":"Camenisch G (2019) Extended clearance model and its use for prospective transporter and enzyme-based hepatic cell stress grading. Int J Pharma Chem 5(2):15\u201319","journal-title":"Int J Pharma Chem"},{"issue":"2","key":"3895_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/toxsci\/kfx284","volume":"162","author":"R Chan","year":"2018","unstructured":"Chan R, Benet LZ (2018) Measures of BSEP inhibition in vitro are not useful predictors of DILI. Toxicol Sci 162(2):499\u2013508. https:\/\/doi.org\/10.1093\/toxsci\/kfx284","journal-title":"Toxicol Sci"},{"issue":"15\u201316","key":"3895_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.drudis.2011.05.007","volume":"16","author":"M Chen","year":"2011","unstructured":"Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W (2011) FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 16(15\u201316):697\u2013703. https:\/\/doi.org\/10.1016\/j.drudis.2011.05.007","journal-title":"Drug Discov Today"},{"issue":"4","key":"3895_CR8","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.drudis.2016.02.015","volume":"21","author":"M Chen","year":"2016","unstructured":"Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 21(4):648\u2013653. https:\/\/doi.org\/10.1016\/j.drudis.2016.02.015","journal-title":"Drug Discov Today"},{"issue":"3","key":"3895_CR9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1152\/ajpgi.00417.2002","volume":"284","author":"JY Chiang","year":"2003","unstructured":"Chiang JY (2003) Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors. Am J Physiol Gastrointest Liver Physiol 284(3):349\u2013356","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"10","key":"3895_CR10","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1194\/jlr.R900010-JLR200","volume":"50","author":"JY Chiang","year":"2009","unstructured":"Chiang JY (2009) Bile acids: regulation of synthesis. J Lipid Res 50(10):1955\u20131966. https:\/\/doi.org\/10.1194\/jlr.R900010-JLR200","journal-title":"J Lipid Res"},{"issue":"9","key":"3895_CR11","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.bbalip.2010.06.002","volume":"1801","author":"PA Dawson","year":"2010","unstructured":"Dawson PA, Hubbert ML, Rao A (2010) Getting the mOST from OST: role of organic solute transporter, OSTalpha-OSTbeta, in bile acid and steroid metabolism. Biochim Biophys Acta 1801(9):994\u20131004. https:\/\/doi.org\/10.1016\/j.bbalip.2010.06.002","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"3895_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1124\/dmd.111.040758","volume":"40","author":"S Dawson","year":"2012","unstructured":"Dawson S, Stahl S, Paul N, Barber J, Kenna JG (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40(1):130\u2013138. https:\/\/doi.org\/10.1124\/dmd.111.040758","journal-title":"Drug Metab Dispos"},{"key":"3895_CR13","first-page":"1","volume":"1","author":"B Efron","year":"1986","unstructured":"Efron B, Tibshirani R (1986) The bootstrap method for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1:1\u201335","journal-title":"Stat Sci"},{"issue":"8","key":"3895_CR14","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1124\/dmd.107.018663","volume":"36","author":"OA Fahmi","year":"2008","unstructured":"Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, Nettleton D (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36(8):1698\u20131708. https:\/\/doi.org\/10.1124\/dmd.107.018663","journal-title":"Drug Metab Dispos"},{"key":"3895_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2020.152445","volume":"437","author":"X Fan","year":"2020","unstructured":"Fan X, Bai J, Hu M, Xu Y, Zhao S, Sun, Y.,\u2026Li, Y. (2020) Drug interaction study of flavonoids toward OATP1B1 and their 3D structure activity relationship analysis for predicting hepatoprotective effects. Toxicology 437:152445. https:\/\/doi.org\/10.1016\/j.tox.2020.152445","journal-title":"Toxicology"},{"issue":"16","key":"3895_CR16","doi-asserted-by":"publisher","first-page":"10046","DOI":"10.1074\/jbc.273.16.10046","volume":"273","author":"T Gerloff","year":"1998","unstructured":"Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, Meier PJ (1998) The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273(16):10046\u201310050. https:\/\/doi.org\/10.1074\/jbc.273.16.10046","journal-title":"J Biol Chem"},{"issue":"1","key":"3895_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/toxsci\/kfs188","volume":"129","author":"R Greupink","year":"2012","unstructured":"Greupink R, Nabuurs SB, Zarzycka B, Verweij V, Monshouwer M, Huisman MT, Russel FG (2012) In silico identification of potential cholestasis-inducing agents via modeling of Na(+)-dependent taurocholate cotransporting polypeptide substrate specificity. Toxicol Sci 129(1):35\u201348. https:\/\/doi.org\/10.1093\/toxsci\/kfs188","journal-title":"Toxicol Sci"},{"issue":"11","key":"3895_CR19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1124\/dmd.120.000086","volume":"48","author":"MJ Hafey","year":"2020","unstructured":"Hafey MJ, Houle R, Tanis KQ, Knemeyer I, Shang J, Chen Q, Evers R (2020) A two-tiered in vitro approach to de-risk drug candidates for potential bile salt export pump inhibition liabilities in drug discovery. Drug Metab Dispos 48(11):1147\u20131160. https:\/\/doi.org\/10.1124\/dmd.120.000086","journal-title":"Drug Metab Dispos"},{"issue":"1\u20132","key":"3895_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3109\/03602539409029805","volume":"26","author":"JA Hinson","year":"1994","unstructured":"Hinson JA, Pumford NR, Nelson SD (1994) The role of metabolic activation in drug toxicity. Drug Metab Rev 26(1\u20132):395\u2013412. https:\/\/doi.org\/10.3109\/03602539409029805","journal-title":"Drug Metab Rev"},{"issue":"4","key":"3895_CR21","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1074\/jbc.275.4.2905","volume":"275","author":"T Hirohashi","year":"2000","unstructured":"Hirohashi T, Suzuki H, Takikawa H, Sugiyama Y (2000) ATP-dependent transport of bile salts by rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 275(4):2905\u20132910. https:\/\/doi.org\/10.1074\/jbc.275.4.2905","journal-title":"J Biol Chem"},{"issue":"6","key":"3895_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1124\/dmd.104.003715","volume":"33","author":"K Ito","year":"2005","unstructured":"Ito K, Hallifax D, Obach RS, Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33(6):837\u2013844. https:\/\/doi.org\/10.1124\/dmd.104.003715","journal-title":"Drug Metab Dispos"},{"key":"3895_CR23","doi-asserted-by":"publisher","first-page":"105533","DOI":"10.1016\/j.tiv.2022.105533","volume":"87","author":"V Kastrinou Lampou","year":"2022","unstructured":"Kastrinou Lampou V, Poller B, Huth F, Fischer A, Kullak-Ublick GA, Arand M, Camenisch G (2022) Novel insights into bile acid detoxification via CYP, UGT and SULT enzymes. Toxicol in Vitro 87:105533. https:\/\/doi.org\/10.1016\/j.tiv.2022.105533","journal-title":"Toxicol in Vitro"},{"key":"3895_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-024-03794-3","author":"V Kastrinou-Lampou","year":"2024","unstructured":"Kastrinou-Lampou V, Rodr\u00edguez-P\u00e9rez R, Poller B, Huth F, G\u00e1borik Z, M\u00e1rtonn\u00e9-T\u00f3th B, Camenisch G (2024) Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC). Arch Toxicol. https:\/\/doi.org\/10.1007\/s00204-024-03794-3","journal-title":"Arch Toxicol"},{"issue":"5","key":"3895_CR25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2011.164","volume":"90","author":"S Katzenmaier","year":"2011","unstructured":"Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G (2011) Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther 90(5):666\u2013673. https:\/\/doi.org\/10.1038\/clpt.2011.164","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3895_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092209","volume":"9","author":"J Keilwagen","year":"2014","unstructured":"Keilwagen J, Grosse I, Grau J (2014) Area under precision-recall curves for weighted and unweighted data. PLoS ONE 9(3):e92209. https:\/\/doi.org\/10.1371\/journal.pone.0092209","journal-title":"PLoS ONE"},{"issue":"3","key":"3895_CR27","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1021\/acs.jcim.6b00518","volume":"57","author":"E Kotsampasakou","year":"2017","unstructured":"Kotsampasakou E, Ecker GF (2017) Predicting drug-induced cholestasis with the help of hepatic transporters-an in silico modeling approach. J Chem Inf Model 57(3):608\u2013615. https:\/\/doi.org\/10.1021\/acs.jcim.6b00518","journal-title":"J Chem Inf Model"},{"issue":"6","key":"3895_CR28","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","volume":"66","author":"GA Kullak-Ublick","year":"2017","unstructured":"Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP (2017) Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut 66(6):1154\u20131164. https:\/\/doi.org\/10.1136\/gutjnl-2016-313369","journal-title":"Gut"},{"issue":"1","key":"3895_CR29","doi-asserted-by":"publisher","first-page":"G271","DOI":"10.1152\/ajpgi.00075.2007","volume":"293","author":"C Mahagita","year":"2007","unstructured":"Mahagita C, Grassl SM, Piyachaturawat P, Ballatori N (2007) Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. Am J Physiol Gastrointest Liver Physiol 293(1):G271-278. https:\/\/doi.org\/10.1152\/ajpgi.00075.2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"3895_CR30","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/toxsci\/kft176","volume":"136","author":"RE Morgan","year":"2013","unstructured":"Morgan RE, van Staden CJ, Chen Y, Kalyanaraman N, Kalanzi J, Dunn RT, Hamadeh HK (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci 136(1):216\u2013241. https:\/\/doi.org\/10.1093\/toxsci\/kft176","journal-title":"Toxicol Sci"},{"issue":"3","key":"3895_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/1386207318666150305144650","volume":"18","author":"C Muller","year":"2015","unstructured":"Muller C, Pekthong D, Alexandre E, Marcou G, Horvath D, Richert L, Varnek A (2015) Prediction of drug induced liver injury using molecular and biological descriptors. Comb Chem High Throughput Screen 18(3):315\u2013322. https:\/\/doi.org\/10.2174\/1386207318666150305144650","journal-title":"Comb Chem High Throughput Screen"},{"issue":"9","key":"3895_CR32","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1124\/dmd.109.027797","volume":"37","author":"S Nakayama","year":"2009","unstructured":"Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Okazaki O (2009) A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos 37(9):1970\u20131977. https:\/\/doi.org\/10.1124\/dmd.109.027797","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"3895_CR33","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00424-006-0109-y","volume":"453","author":"AT Nies","year":"2007","unstructured":"Nies AT, Keppler D (2007) The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 453(5):643\u2013659. https:\/\/doi.org\/10.1007\/s00424-006-0109-y","journal-title":"Pflugers Arch"},{"key":"3895_CR34","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1146\/annurev-pharmtox-011613-140021","volume":"54","author":"ND Pfeifer","year":"2014","unstructured":"Pfeifer ND, Hardwick RN, Brouwer KL (2014) Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics. Annu Rev Pharmacol Toxicol 54:509\u2013535. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011613-140021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3895_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/9781119171003.ch15","volume-title":"Transporters and drug-metabolizing enzymes in drug toxicity","author":"B Poller","year":"2021","unstructured":"Poller B, Huth F, Kastrinou-Lampou V, Kullak-Ublick GA, Arand M, Camenisch G (2021) The extended clearance model. In: Li AP (ed) Transporters and drug-metabolizing enzymes in drug toxicity. Wiley, pp 455\u2013479"},{"issue":"1","key":"3895_CR36","first-page":"1019","volume":"2","author":"AR Rahimi","year":"2014","unstructured":"Rahimi AR (2014) Primidone and liver abnormalities: a case study. J Pharmacol Clin Toxicol 2(1):1019","journal-title":"J Pharmacol Clin Toxicol"},{"issue":"1","key":"3895_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1517\/17425255.3.1.51","volume":"3","author":"RJ Riley","year":"2007","unstructured":"Riley RJ, Grime K, Weaver R (2007) Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3(1):51\u201366. https:\/\/doi.org\/10.1517\/17425255.3.1.51","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"3895_CR38","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1021\/tx5000393","volume":"27","author":"T Ritschel","year":"2014","unstructured":"Ritschel T, Hermans SM, Schreurs M, van den Heuvel JJ, Koenderink JB, Greupink R, Russel FG (2014) In silico identification and in vitro validation of potential cholestatic compounds through 3D ligand-based pharmacophore modeling of BSEP inhibitors. Chem Res Toxicol 27(5):873\u2013881. https:\/\/doi.org\/10.1021\/tx5000393","journal-title":"Chem Res Toxicol"},{"key":"3895_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev.biochem.72.121801.161712","volume":"72","author":"DW Russell","year":"2003","unstructured":"Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 72:137\u2013174. https:\/\/doi.org\/10.1146\/annurev.biochem.72.121801.161712","journal-title":"Annu Rev Biochem"},{"issue":"23","key":"3895_CR40","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.2174\/092986709788803097","volume":"16","author":"S Russmann","year":"2009","unstructured":"Russmann S, Kullak-Ublick GA, Grattagliano I (2009) Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 16(23):3041\u20133053. https:\/\/doi.org\/10.2174\/092986709788803097","journal-title":"Curr Med Chem"},{"key":"3895_CR41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.tiv.2016.02.019","volume":"33","author":"J Saito","year":"2016","unstructured":"Saito J, Okamura A, Takeuchi K, Hanioka K, Okada A, Ohata T (2016) High content analysis assay for prediction of human hepatotoxicity in HepaRG and HepG2 cells. Toxicol in Vitro 33:63\u201370. https:\/\/doi.org\/10.1016\/j.tiv.2016.02.019","journal-title":"Toxicol in Vitro"},{"issue":"3","key":"3895_CR42","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/hep.29888","volume":"68","author":"D Slijepcevic","year":"2018","unstructured":"Slijepcevic D, Roscam Abbing RLP, Fuchs CD, Haazen LCM, Beuers U, Trauner M, van de Graaf SFJ (2018) Na(+) -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice. Hepatology 68(3):1057\u20131069. https:\/\/doi.org\/10.1002\/hep.29888","journal-title":"Hepatology"},{"issue":"4","key":"3895_CR43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1517\/17425255.2011.557067","volume":"7","author":"B Stieger","year":"2011","unstructured":"Stieger B, Geier A (2011) Genetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis. Expert Opin Drug Metab Toxicol 7(4):411\u2013425. https:\/\/doi.org\/10.1517\/17425255.2011.557067","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"3895_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169719","volume":"12","author":"T Suga","year":"2017","unstructured":"Suga T, Yamaguchi H, Sato T, Maekawa M, Goto J, Mano N (2017) Preference of conjugated bile acids over unconjugated bile acids as substrates for OATP1B1 and OATP1B3. PLoS ONE 12(1):e0169719. https:\/\/doi.org\/10.1371\/journal.pone.0169719","journal-title":"PLoS ONE"},{"issue":"3","key":"3895_CR45","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s11095-009-0026-9","volume":"27","author":"T Tachibana","year":"2010","unstructured":"Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S, Sugiyama Y (2010) Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res 27(3):442\u2013446. https:\/\/doi.org\/10.1007\/s11095-009-0026-9","journal-title":"Pharm Res"},{"key":"3895_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010029","author":"P Tatrai","year":"2022","unstructured":"Tatrai P, Erdo F, Krajcsi P (2022) Role of hepatocyte transporters in drug-induced liver injury (DILI)-in vitro testing. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15010029","journal-title":"Pharmaceutics"},{"issue":"8","key":"3895_CR47","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrd2619","volume":"7","author":"C Thomas","year":"2008","unstructured":"Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K (2008) Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7(8):678\u2013693. https:\/\/doi.org\/10.1038\/nrd2619","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"3895_CR48","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1152\/physrev.00027.2002","volume":"83","author":"M Trauner","year":"2003","unstructured":"Trauner M, Boyer JL (2003) Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83(2):633\u2013671. https:\/\/doi.org\/10.1152\/physrev.00027.2002","journal-title":"Physiol Rev"},{"issue":"1","key":"3895_CR49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cld.2019.09.003","volume":"24","author":"PB Watkins","year":"2020","unstructured":"Watkins PB (2020) Quantitative systems toxicology approaches to understand and predict drug-induced liver injury. Clin Liver Dis 24(1):49\u201360. https:\/\/doi.org\/10.1016\/j.cld.2019.09.003","journal-title":"Clin Liver Dis"},{"key":"3895_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-1-0716-2265-0_9","volume":"2486","author":"PB Watkins","year":"2022","unstructured":"Watkins PB (2022) Quantitative systems toxicology and drug development: the DILIsym experience. Methods Mol Biol 2486:181\u2013196. https:\/\/doi.org\/10.1007\/978-1-0716-2265-0_9","journal-title":"Methods Mol Biol"},{"issue":"2","key":"3895_CR51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/toxsci\/kfx060","volume":"157","author":"RW Yucha","year":"2017","unstructured":"Yucha RW, He K, Shi Q, Cai L, Nakashita Y, Xia CQ, Liao M (2017) In Vitro drug-induced liver injury prediction: criteria optimization of efflux transporter IC50 and physicochemical properties. Toxicol Sci 157(2):487\u2013499. https:\/\/doi.org\/10.1093\/toxsci\/kfx060","journal-title":"Toxicol Sci"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03895-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-024-03895-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03895-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T17:28:07Z","timestamp":1737134887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-024-03895-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3895"],"URL":"https:\/\/doi.org\/10.1007\/s00204-024-03895-z","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}